Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer

被引:44
|
作者
Burrell, Rebecca A. [1 ]
Juul, Nicolai [2 ]
Johnston, Stephen R. [3 ]
Reis-Filho, Jorge S. [4 ]
Szallasi, Zoltan [2 ,5 ]
Swanton, Charles [1 ,3 ]
机构
[1] London Res Inst, Translat Canc Therapeut Lab, London WC2A 3PX, England
[2] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark
[3] Royal Marsden Hosp, Breast Unit, Dept Med, Sutton SM2 5PT, Surrey, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol CHIP HST, Childrens Hosp Informat Program, Boston, MA 02115 USA
关键词
CHROMOSOMAL INSTABILITY; HER2; BREAST CANCER; DRUG RESISTANCE; TUMOUR HETEROGENEITY; MICROTUBULE; CEP17; SPINDLE ASSEMBLY CHECKPOINT; TAXOL-INDUCED APOPTOSIS; IN-SITU HYBRIDIZATION; PHASE-II TRIAL; MITOTIC CHECKPOINT; 1ST-LINE TREATMENT; INTRATUMORAL HETEROGENEITY; RETROSPECTIVE ANALYSIS; KARYOTYPIC COMPLEXITY; ADJUVANT CHEMOTHERAPY;
D O I
10.1002/jcb.22781
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosomal instability (CIN) is a common cause of tumour heterogeneity and poor prognosis in solid tumours and describes cell-cell variation in chromosome structure or number across a tumour population. In this article we consider evidence suggesting that CIN may be targeted and may influence response to distinct chemotherapy regimens, using HER2-positive breast cancer as an example. Pre-clinical models have indicated a role for HER2 signalling in initiating CIN and defective cell-cycle control, and evidence suggests that HER2-targeting may attenuate this process. Anthracyclines and platinum agents may target tumours with distinct patterns of karyotypic complexity, whereas taxanes may have preferential activity in tumours with relative chromosomal stability. A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer. J. Cell. Biochem. 111: 782-790, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:782 / 790
页数:9
相关论文
共 50 条
  • [11] Targeting HER2-positive breast cancer: advances and future directions
    Sandra M. Swain
    Mythili Shastry
    Erika Hamilton
    Nature Reviews Drug Discovery, 2023, 22 : 101 - 126
  • [12] Targeting SHP2 for the treatment of HER2-positive breast cancer
    Agazie, Y.
    Hartman, Z.
    CANCER RESEARCH, 2019, 79 (04)
  • [13] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
    Sadeghi, Saeed
    Olevsky, Olga
    Hurvitz, Sara A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 329 - 338
  • [14] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [15] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    BREAST, 2014, 23 (02): : 128 - 136
  • [16] Inflammatory HER2-positive breast cancer
    Dirix, Luc Y.
    Vermeulen, Peter B.
    LANCET ONCOLOGY, 2012, 13 (04): : 324 - 326
  • [17] Margetuximab for HER2-Positive Breast Cancer
    Cuellar, Sandra
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 573 - 575
  • [18] HER2-positive advanced breast cancer
    Robert, Nicholas J.
    Favret, Anne M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 293 - +
  • [19] Lapatinib in HER2-positive breast cancer
    Nelson, Roxanne
    LANCET ONCOLOGY, 2018, 19 (01): : 22 - 22
  • [20] Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer
    Blasco-Benito, Sandra
    Moreno, Estefania
    Seijo-Vila, Marta
    Tundidor, Isabel
    Andradas, Clara
    Caffarel, Maria M.
    Caro-Villalobos, Miriam
    Uriguen, Leyre
    Diez-Alarcia, Rebeca
    Moreno-Bueno, Gema
    Hernandez, Lucia
    Manso, Luis
    Homar-Ruano, Patricia
    McCormick, Peter J.
    Bibic, Lucka
    Bernado-Morales, Cristina
    Arribas, Joaquin
    Canals, Meritxell
    Casado, Vicent
    Canela, Enric I.
    Guzman, Manuel
    Perez-Gomez, Eduardo
    Sanchez, Cristina
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (09) : 3863 - 3872